| Drug General Information |
| Drug ID |
D0ZK7B
|
| Former ID |
DIB006312
|
| Drug Name |
Tesofensine
|
| Synonyms |
NS-2330
|
| Drug Type |
Small molecular drug
|
| Indication |
Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89]
|
Phase 2 |
[1]
|
|---|
| Company |
NeuroSearch A/S
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H23Cl2NO
|
| CAS Number |
CAS 195875-84-4
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Insulin receptor |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Adherens junction
|
|
Insulin signaling pathway
|
|
Ovarian steroidogenesis
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Aldosterone-regulated sodium reabsorption
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling Pathway
|
|
PANTHER Pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
|
PI3 kinase pathway
|
|
Pathway Interaction Database
|
Insulin Pathway
|
|
Signaling events mediated by PTP1B
|
|
Signaling events mediated by TCPTP
|
|
Insulin-mediated glucose transport
|
|
PathWhiz Pathway
|
Insulin Signalling
|
|
Leucine Stimulation on Insulin Signaling
|
|
Reactome
|
IRS activation
|
|
Signal attenuation
|
|
Insulin receptor signalling cascade
|
|
Insulin receptor recycling
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Insulin Signaling
|
|
Nanoparticle triggered autophagic cell death
|
|
AGE/RAGE pathway
|
|
Signaling by Insulin receptor
|
|
Folate Metabolism
|
|
Type II diabetes mellitus
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
|
AMPK Signaling
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00153010) An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type. U.S. National Institutes of Health. |
|---|
| REF 2 | The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010 Jun 25;636(1-3):88-95. |
|---|
